ArticleCureus2026
Population-Level Survival Trends in Hematologic Malignancies: A Surveillance, Epidemiology, and End Results (SEER) Analysis of 494,244 Patients From 2000 to 2020.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population-level survival gains from transformative advances in hematologic malignancy treatment may not be equitably distributed. We examined over two decades of survival trends for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma using data from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) 17 Registries (2000-2020). Kaplan-Meier analysis estimated overall survival (OS) for 423,982 patients aged ≥15 years, stratified by diagnosis year, race/ethnicity, age, sex, and stage; observed OS reflects all-cause mortality. Multivariate Cox proportional hazards regression was performed on 494,244 patients to identify independent correlates of all-cause mortality. Five-year OS improved substantially from 2000 to 2017: myeloma (29.0%→53.7%, +85% relative improvement), ALL (30.7%→53.0%, +73%), AML (15.2%→27.9%, +84%), and NHL (54.5%→65.6%, +20%). Age ≥70 years was the strongest correlate of mortality (hazard ratio (HR): 7.20; 95% CI: 7.01-7.39 vs. <40 years). Non-Hispanic Black and Hispanic patients had significantly higher mortality than non-Hispanic White patients (HR: 1.22 and 1.11, respectively; both: p < 0.001). Each successive diagnosis period was independently associated with lower mortality (HR: 0.72 for 2015-2020 vs. 2000-2004). Survival has improved substantially but unequally across all four malignancies. Age and race/ethnicity remain independent correlates of mortality after full adjustment, warranting targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.